Aclaris Therapeutics, Inc. Tax Withholding Paid on Stock Awards
Aclaris Therapeutics, Inc. (ACRS) reported Tax Withholding Paid on Stock Awards of $273.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $23.00K, a 155.56% increase year-over-year.
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $250.00K, a 9.09% decline year-over-year.
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $162.00K, a 51.35% decline year-over-year.
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $446.00K, a 9.05% increase from fiscal 2024.
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $409.00K, a 300.98% increase from fiscal 2023.
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $102.00K, a 200.00% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $34.00K, a 98.91% decline from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $273.00K 10-Q · filed 2026-08-06 | $435.00K derived: sum of 3 quarters · filed 2026-08-06 | $435.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $250.00K 10-Q · filed 2026-05-07 | $412.00K derived: sum of 2 quarters · filed 2026-05-07 | $412.00K derived: sum of 3 quarters · filed 2026-05-07 | $421.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $162.00K derived: sum of 2 quarters · filed 2026-02-26 | $171.00K derived: sum of 3 quarters · filed 2026-08-06 | $446.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.00K derived: sum of 2 quarters · filed 2026-08-06 | $284.00K 10-Q · filed 2025-11-06 | $617.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $284.00K 10-Q · filed 2026-08-06 | $617.00K derived: sum of 3 quarters · filed 2026-08-06 | $627.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $275.00K 10-Q · filed 2026-05-07 | $608.00K derived: sum of 2 quarters · filed 2026-05-07 | $618.00K derived: sum of 3 quarters · filed 2026-05-07 | $629.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $343.00K derived: sum of 2 quarters · filed 2026-02-26 | $354.00K derived: sum of 3 quarters · filed 2026-02-26 | $409.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $21.00K derived: sum of 2 quarters · filed 2025-11-06 | $76.00K 10-Q · filed 2025-11-06 | $76.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $66.00K 10-Q · filed 2025-08-07 | $66.00K derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $55.00K 10-Q · filed 2025-05-08 | $55.00K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $102.00K 10-K · filed 2025-02-27 | ||
| 2023-09-30 | $102.00K 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $11.00K derived: sum of 2 quarters · filed 2024-02-27 | $27.00K derived: sum of 3 quarters · filed 2024-02-27 | $34.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $27.00K derived: sum of 2 quarters · filed 2023-11-06 | $34.00K 10-Q · filed 2023-11-06 | $36.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $23.00K 10-Q · filed 2023-08-07 | $25.00K derived: sum of 3 quarters · filed 2024-02-27 | $109.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $7.00K 10-Q · filed 2023-05-08 | $9.00K derived: sum of 2 quarters · filed 2024-02-27 | $93.00K derived: sum of 3 quarters · filed 2024-02-27 | $117.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $86.00K derived: sum of 2 quarters · filed 2024-02-27 | $110.00K derived: sum of 3 quarters · filed 2024-02-27 | $3.12M 10-K · filed 2024-02-27 |
| 2021-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $108.00K derived: sum of 2 quarters · filed 2022-11-08 | $3.12M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $3.04M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $3.01M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |